Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight

AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosal, Samit, Sinha, Binayak, Mukherjee, Rik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/
https://www.ncbi.nlm.nih.gov/pubmed/36707061
http://dx.doi.org/10.1002/ehf2.14296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/
https://www.ncbi.nlm.nih.gov/pubmed/36707061
http://dx.doi.org/10.1002/ehf2.14296

Ejemplares similares